PMID- 25979110
OWN - NLM
STAT- MEDLINE
DCOM- 20160418
LR  - 20220311
IS  - 1746-045X (Electronic)
IS  - 1746-0441 (Linking)
VI  - 10
IP  - 9
DP  - 2015
TI  - The discovery and development of omalizumab for the treatment of asthma.
PG  - 1033-42
LID - 10.1517/17460441.2015.1048220 [doi]
AB  - INTRODUCTION: The evolution in immunological methods used to assess human 
      allergic diseases has led to the identification of immunoglobulin E (IgE) as a 
      diagnostic biomarker and a potential therapeutic target. Innovative technologies 
      in molecular biology and immunogenetics contributed to the development of a 
      selective blocking agent, disclosing new therapeutic perspectives in the 
      treatment of allergic asthma. Omalizumab is the most advanced humanized anti-IgE 
      monoclonal antibody that specifically binds serum-free IgE. Omalizumab also 
      interrupts the allergic cascade by preventing binding of IgE with FcepsilonRI receptors 
      on mast cells, basophils, antigen-presenting cells and other inflammatory cells. 
      AREAS COVERED: This review discusses the discovery strategy and preclinical 
      development of omalizumab. Furthermore, it also provides a clinical overview of 
      the key trials leading to its launch and a detailed analysis of safety and 
      post-marketing data. EXPERT OPINION: The clinical efficacy of omalizumab in 
      allergic asthma has been well documented in clinical trials, involving adults, 
      adolescents and children with moderate-to-severe and severe allergic asthma. To 
      date, omalizumab has also been approved in chronic idiopathic urticaria for 
      patients 12 years and older who remain symptomatic despite high dosages of H1 
      antihistamines. Omalizumab has also been investigated in many other different 
      patient populations beyond allergic asthma and may yet have an application to 
      other indications. While omalizumab is the only mAb available for treating 
      allergic asthma, the authors anticipate that new mAbs will emerge in the future 
      that overcome omalizumab's current limitations.
FAU - Licari, Amelia
AU  - Licari A
AD  - University of Pavia, Foundation IRCCS Policlinico San Matteo, Department of 
      Pediatrics , Pavia , Italy.
FAU - Marseglia, GianLuigi
AU  - Marseglia G
FAU - Castagnoli, Riccardo
AU  - Castagnoli R
FAU - Marseglia, Alessia
AU  - Marseglia A
FAU - Ciprandi, Giorgio
AU  - Ciprandi G
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150515
PL  - England
TA  - Expert Opin Drug Discov
JT  - Expert opinion on drug discovery
JID - 101295755
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Anti-Allergic Agents/adverse effects/pharmacology/therapeutic use
MH  - Anti-Asthmatic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Asthma/*drug therapy/immunology
MH  - Child
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Omalizumab/adverse effects/pharmacology/*therapeutic use
OTO - NOTNLM
OT  - allergic asthma
OT  - anti-IgE therapy
OT  - omalizumab
EDAT- 2015/05/17 06:00
MHDA- 2016/04/19 06:00
CRDT- 2015/05/17 06:00
PHST- 2015/05/17 06:00 [entrez]
PHST- 2015/05/17 06:00 [pubmed]
PHST- 2016/04/19 06:00 [medline]
AID - 10.1517/17460441.2015.1048220 [doi]
PST - ppublish
SO  - Expert Opin Drug Discov. 2015;10(9):1033-42. doi: 10.1517/17460441.2015.1048220. 
      Epub 2015 May 15.